Jan Reckweg
Clinical Researcher and Psychopharmacologist
Papers
Trials
Key Impact
Notable for leading and co‑authoring early‑phase clinical investigations of short‑acting tryptamines (notably vaporised 5‑MeO‑DMT/GH001), and for contributions to safety, psychometric and neuroimaging research in contemporary psychedelic science.
Background & Research
Jan Reckweg is a clinical researcher and psychopharmacologist whose work focuses on the clinical pharmacology, safety profiling and experiential measurement of contemporary and classical psychedelics. He has co‑authored multiple phase 1 and phase 1/2 studies evaluating a vapourised 5‑methoxy‑N,N‑dimethyltryptamine formulation (GH001) in both healthy volunteers and patients with treatment‑resistant depression, including dose‑ranging safety and psychoactive‑effect characterisations and a phase 1/2 efficacy assessment. Reckweg has also contributed to comparative acute‑effects studies (for example 2C‑B versus psilocybin), investigations of structural brain differences associated with repeated ayahuasca use, and the development and evaluation of rapid assessment tools such as a peak‑experience scale for 5‑MeO‑DMT.